Amble may ask for full-body selfie images to verify that your reported weight is consistent
Build relationships with your pharmacy
Cardiovascular and non- cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta- analysis of randomized controlled cardiovascular outcome trials
After 4 weeks at therapeutic doses, most users report 50-70% reduction in pain, significantly improved function, and ability to resume modified training or activities
Other common side effects reported in 5% or more of people in clinical trials include: Digestive system Indigestion (dyspepsia) Abdominal pain or upper abdominal pain Gastroenteritis (stomach bug) Increased lipase levels (a pancreatic enzyme, detected on blood tests) General Headache Fatigue (feeling tired) Dizziness Fever Other Injection site reactions such as redness, irritation, or bruising Low blood sugar (hypoglycemia), particularly if you also take insulin or a sulfonylurea Contact your doctor if any side effects are severe, persistent, or affecting your daily life
doi: 10.1159/000521264 Summary Keywords GLP-1R agonists, obesity, weight-reducing drugs, metabolic diseases, dual agonism Citation Wang J-Y, Wang Q-W, Yang X-Y, Yang W, Li D-R, Jin J-Y, Zhang H-C and Zhang X-F (2023) GLP1 receptor agonists for the treatment of obesity: Role as a promising approach